Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia

• Główni autorzy: Changyu Pan (Autor), Hyung Joon Yoo (Autor), Low-Tone Ho (Autor)
• Format: Książka
• Wydane: Hindawi Limited, 2011-01-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg/m2 or greater w...